192 related articles for article (PubMed ID: 11211608)
1. Using a continuous transformation of the Breslow thickness for prognosis in cutaneous melanoma.
Vollmer RT; Seigler HF
Am J Clin Pathol; 2001 Feb; 115(2):205-12. PubMed ID: 11211608
[TBL] [Abstract][Full Text] [Related]
2. Breslow thickness and clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging.
Marghoob AA; Koenig K; Bittencourt FV; Kopf AW; Bart RS
Cancer; 2000 Feb; 88(3):589-95. PubMed ID: 10649252
[TBL] [Abstract][Full Text] [Related]
3. Prognostic variables and prognostic groups for malignant melanoma. The information from Cox and Classification And Regression Trees analysis: an Italian population-based study.
Crocetti E; Mangone L; Lo Scocco G; Carli P
Melanoma Res; 2006 Oct; 16(5):429-33. PubMed ID: 17013092
[TBL] [Abstract][Full Text] [Related]
4. Identification of higher risk thin melanomas should be based on Breslow depth not Clark level IV.
Owen SA; Sanders LL; Edwards LJ; Seigler HF; Tyler DS; Grichnik JM
Cancer; 2001 Mar; 91(5):983-91. PubMed ID: 11251950
[TBL] [Abstract][Full Text] [Related]
5. Classification of localized melanoma by the exponential survival trees method.
Huang X; Soong S; McCarthy WH; Urist MM; Balch CM
Cancer; 1997 Mar; 79(6):1122-8. PubMed ID: 9070489
[TBL] [Abstract][Full Text] [Related]
6. Predicting five-year outcome for patients with cutaneous melanoma in a population-based study.
Barnhill RL; Fine JA; Roush GC; Berwick M
Cancer; 1996 Aug; 78(3):427-32. PubMed ID: 8697387
[TBL] [Abstract][Full Text] [Related]
7. Impact of ulceration in stages I to III cutaneous melanoma as staged by the American Joint Committee on Cancer Staging System: an analysis of the German Central Malignant Melanoma Registry.
Eigentler TK; Buettner PG; Leiter U; Garbe C;
J Clin Oncol; 2004 Nov; 22(21):4376-83. PubMed ID: 15514379
[TBL] [Abstract][Full Text] [Related]
8. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
[TBL] [Abstract][Full Text] [Related]
9. Sentinel node status in melanoma patients is not predictive for overall survival upon multivariate analysis.
Roka F; Kittler H; Cauzig P; Hoeller C; Hinterhuber G; Wolff K; Pehamberger H; Diem E
Br J Cancer; 2005 Feb; 92(4):662-7. PubMed ID: 15700039
[TBL] [Abstract][Full Text] [Related]
10. Development of prognostic factors and survival in cutaneous melanoma over 25 years: An analysis of the Central Malignant Melanoma Registry of the German Dermatological Society.
Buettner PG; Leiter U; Eigentler TK; Garbe C
Cancer; 2005 Feb; 103(3):616-24. PubMed ID: 15630700
[TBL] [Abstract][Full Text] [Related]
11. The prognostic importance of tumor mitotic rate confirmed in 1317 patients with primary cutaneous melanoma and long follow-up.
Francken AB; Shaw HM; Thompson JF; Soong SJ; Accortt NA; Azzola MF; Scolyer RA; Milton GW; McCarthy WH; Colman MH; McGovern VJ
Ann Surg Oncol; 2004 Apr; 11(4):426-33. PubMed ID: 15070604
[TBL] [Abstract][Full Text] [Related]
12. [Viewpoint of the Dutch Melanoma Working Group regarding sentinel lymph node biopsy: prognostic but not therapeutic implications].
Kruit WH;
Ned Tijdschr Geneeskd; 2008 Mar; 152(10):574-6. PubMed ID: 18402325
[TBL] [Abstract][Full Text] [Related]
13. Mitotic rate in melanoma: a reexamination.
Attis MG; Vollmer RT
Am J Clin Pathol; 2007 Mar; 127(3):380-4. PubMed ID: 17276944
[TBL] [Abstract][Full Text] [Related]
14. Survival analysis of malignant melanoma in Japan--multivariate analysis of prognostic factors.
Uehara S; Kamo R; Harada T; Ishii M
Osaka City Med J; 2009 Jun; 55(1):35-52. PubMed ID: 19725433
[TBL] [Abstract][Full Text] [Related]
15. Interobserver variation in the histopathologic reporting of key prognostic parameters, particularly clark level, affects pathologic staging of primary cutaneous melanoma.
Murali R; Hughes MT; Fitzgerald P; Thompson JF; Scolyer RA
Ann Surg; 2009 Apr; 249(4):641-7. PubMed ID: 19300224
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the german dermatological society.
Leiter U; Buettner PG; Eigentler TK; Garbe C
J Clin Oncol; 2004 Sep; 22(18):3660-7. PubMed ID: 15302905
[TBL] [Abstract][Full Text] [Related]
17. [Experiences with the new American Joint Committee on Cancer (AJCC) classification of cutaneous melanoma].
Eigentler TK; Radny P; Kamin A; Weide B; Caroli UM; Garbe C
J Dtsch Dermatol Ges; 2005 Aug; 3(8):592-8. PubMed ID: 16033477
[TBL] [Abstract][Full Text] [Related]
18. [Sentinel lymph node biopsy for melanoma: prognostic value and disadvantages in 300 patients].
de Vries M; Jager PL; Suurmeijer AJ; Plukker JT; van Ginkel RJ; Hoekstra HJ
Ned Tijdschr Geneeskd; 2005 Aug; 149(33):1845-51. PubMed ID: 16128183
[TBL] [Abstract][Full Text] [Related]
19. Primary cutaneous melanoma. Optimized cutoff points of tumor thickness and importance of Clark's level for prognostic classification.
Büttner P; Garbe C; Bertz J; Burg G; d'Hoedt B; Drepper H; Guggenmoos-Holzmann I; Lechner W; Lippold A; Orfanos CE
Cancer; 1995 May; 75(10):2499-2506. PubMed ID: 7736394
[TBL] [Abstract][Full Text] [Related]
20. Volume of malignant melanoma is superior to thickness as a prognostic indicator. Preliminary observation.
Friedman RJ; Rigel DS; Kopf AW; Grin CM; Heilman E; Bart RS; Kamino H; Harris MN; Roses DF; Postel AH
Dermatol Clin; 1991 Oct; 9(4):643-8. PubMed ID: 1934639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]